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Introduction
In 1986, with the development of monoclonal antibod-
ies, the small cells with round nucleus present in the athero-
matous plaque, known before as “small monocytes”, were
demonstrated to be T lymphocytes [1]. Several years later
it was shown that these lymphocytes “recognize” the oxi-
dized molecules of low-density lipoproteins (LDL) –
oxLDL [2]. In 1990, it has been also demonstrated that the
development of atherosclerotic plaques correlates with the
presence of at least two types of infectious microorganisms;
Chlamydia pneumoniae and Herpes simplex virus were
observed [3, 4]. These findings posed the question about
the involvement of the inflammatory process in athero-
sclerosis. Speculations of this kind were initially received
with great skepticism because of the lack of spectacular,
unequivocal evidences of significant, causal role of inflam-
mation in atherogenesis. Such evidence was delivered by
the use of a new technique of gene targeting, for the inven-
tion of which Mario R. Capecchi (Italy), Martin J. Evans
(United Kingdom) and Oliver Smithies (USA) received the
Nobel Prize in Physiology or Medicine in 2007.
Gene targeting enabled to create apolipoprotein E
(apoE)-knockout mice (described later in the text), which
soon turned out to be very good model to test the involve-
ment of inflammation and immune mechanisms in the
development of atherosclerosis. As it was evidenced in sem-
inal paper of Gupta et al., the genetic deletion of only one
cytokine in apoE knockout mice – interferon γ (IFN-γ),
reduced atherosclerosis by 60% [5].
Over the last 15 years, many reports clearly showed the
involvement of various inflammatory mechanisms in the
development of atherosclerotic plaques in apoE knockout
mice: the overexpression of adhesion molecules (vascular
adhesion molecule 1 and intercellular adhesion molecule 1)
at sites with atheromatous changes was observed [6], the
monocyte chemotactic protein (MCP-1) was shown to play
an important part in the progression of atheromatous lesions
[7, 8]. It was also observed that knockout of interleukin-18
decreased atherosclerosis by 35% [9, 10].
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Abstract
Based on the current knowledge it is well ascertained that inflammation backgrounds the pathogenesis
of atherosclerosis. Still, some open questions remain.
Animal model is an important tool to study atherogenesis. Nowadays, genetically modified mice play
a pivotal role. Wild mice are highly resistant to atherosclerosis, whereas “gene-targeted” modified mice
can spontaneously (even without use of high cholesterol diet) develop atherosclerosis. The best example
are apolipoprotein E (apoE)-knockout mice.
In this review we will discuss usefulness of apoE-knockout mice to study the pathogenesis 
of atherosclerotic lesions, especially the immune mechanisms of atherogenesis.
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Early report on apoE-knockout mice showed that inhi-
bition of CD40 signaling reduced atherosclerosis [11]. This
was explained by the fact that ligation of CD40 molecule
[tumor necrosis factor α (TNF-α) receptor superfamily
member] – found in the atheromatous plaque on endothe-
lial cells, vascular smooth muscle cells, antigen-presenting
cells and platelets – with CD40L activates a number of tran-
scription factors involved in inflammatory responses: 
NF-κB, AP-1, STAT-1 or Egr-1. Therefore, CD40-CD40L
ligation may influence the endothelial cells, which, in con-
sequence, acquire proinflammatory and proatherosclerotic
phenotype leading to the expression of adhesion molecules
and tissue factor on their surface. This finding created new
possibilities of therapeutic approach, consisting in inhibi-
tion of the CD40–CD40L pathway [12-14].
Finally, in apoE-knockout mice with severe combined
immunodeficiency (SCID) atherosclerosis was reduced by
70% in comparison to the control group, due to a signifi-
cantly lower number of lymphocytes in mice with SCID.
Moreover, transfer of T cells to these mice aggravated 
athero sclerosis even by 164% [15].
Atherosclerosis as an inflammatory process
These and other facts made the investigators realize
unequivocally that inflammation was essential for athero-
genesis. Therefore, in 1999, just before his death, Russell
Ross (the author of the “chronic response to injury” theory
of atherosclerosis) officially proclaimed that “atheroscle-
rosis is an inflammatory disease” [16].
However, inflammation occurs in response to factors
that destabilize the local vessel wall homeostasis.
The first stage of atherogenesis consists in endothelial
dysfunction. It predominantly involves all the regions of
arterial bifurcations where the blood flow is not laminar.
Disturbed blood flow, causes up-regulation of TLR2 on
endothelial cells favoring inflammatory phenotype [17].
Hence, these localizations are prone to develop atheroscle-
rosis. In such places LDL is accumulated in the suben-
dothelial space. Clearly, lipoprotein accumulation is
increased if the serum LDL level is elevated. Low density
lipoproteins are transported by passive diffusion and their
accumulation in the vascular wall seems to depend on the
interaction between apolipoprotein B of the LDL molecule
and proteoglycans of the matrix [18].
There is evidence that unchanged LDLs are “collected”
by the macrophages too slowly to activate their transfor-
mation into foam cells. Therefore, it has been suggested that
LDL molecule is “modified” within the vascular wall. The
most significant modification is lipid oxidation, resulting
in the formation of so-called “minimally oxidized” LDL
[19]. The generation of these “alien molecules” leads to the
development of inflammatory response, with predominant
participation of monocytes and lymphocytes [20, 21]. The
local inflammation is triggered by accumulation of the min-
imally oxidized LDLs in the subendothelial space, thus stim-
ulating the endothelial cells to produce a number of proin-
flammatory molecules [22].
Hyperlipidemia causes macrophage accumulation in the
blood vessels. Before the “minimally oxidized” LDLs have
been engulfed by the macrophages, they have to be modi-
fied into “highly oxidized” LDL. The macrophage scav-
enger receptors are responsible for the rapid uptake of the
highly modified LDL [23]. Oxidized molecules of low-den-
sity lipoproteins, and also heat shock protein 60 (HSP60)
(endogenous TLR-ligands) and/or bacterial toxins (exoge-
nous TLR-ligands) might trigger Toll-like receptor-depen-
dent macrophage activation in the arterial wall [24, 25].
During the following phase macrophages “present the
antigen” to T lymphocytes. This antigen may be a fragment
of oxidized LDL “digested” by the macrophages, HSP60,
β2-glycoprotein I or the fragments of bacterial antigens [26].
The interaction requires the presence of CD40 receptor on
the surface of macrophages and its ligand CD40L on the
surface of T lymphocytes [27, 28]. It is currently believed
that the immunological response of Th1 type and its medi-
ators (IFN-γ, TNF-α, interleukin-1, interleukin-12, inter-
leukin-18) accelerate atherosclerosis, whereas the response
of Treg type and its mediators (interleukin-10 and TGF-β)
inhibit the development of atherosclerosis [29-31]. There-
fore an idea of vaccination aroused as a future treatment
against atherogenesis [32, 33].
The next phase of atherogenesis is the development of
fibrous atheroma. The deposition of extracellular choles-
terol and its esters is then intensified as well as the migra-
tion of smooth muscle cells from media to intima layer of
artery wall, their proliferation and finally excessive pro-
duction of the extracellular matrix.
A stable atheromatous plaque is most commonly cov-
ered with a fairly thick fibrous layer, protecting the lipid
nucleus from contact with the blood. In an unstable plaque
there is a big lipid nucleus with a fairly thin fibrous layer.
In atheromatous plaque, changed as described above, the
proinflammatory factors produced by T lymphocytes (such
as IFN-γ) seem to play a crucial role. They decrease pro-
duction of the extracellular matrix by smooth muscles and
at the same time increase production of the metallopro-
teinases by macrophages [34].
In a number of reports published so far there has been
a tendency to consider atherogenesis as the effect of dys-
lipidemia or inflammation alone. It is an erroneous dichoto-
my. It should be emphasized that atherosclerosis results from
both lipid disorders and enhanced inflammation. Therefore,
atherosclerosis is a chronic inflammatory disease, in most
cases initiated and aggravated by hypercholesterolemia.
Thus, hypercholesterolemia and inflammation were de -
scribed as “partners in crime” [35].
There are numerous studies reporting that certain strains
of probiotic bacteria reduce cholesterol level both in rodents
and in humans [36-38]. Prebiotics administration (for 16
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weeks) to ApoE–/– mice resulted in the reduction of athero -
sclerotic lesion size [39]. Well documented are anti-inflam-
matory and immunoregulating properties of probiotics
reviewed elsewhere [40, 41]. We have shown that not only
whole probiotic bacteria, but exopolysaccharide (EPS), the
component of the cell wall of Lactobacillus rhamnosus has
immunomodyfying and anti-inflammatory properties, both
in vitro [42] and in vivo [43]. Our preliminary study suggest
that L. rhamnosus EPS decreases atherosclerosis develop-
ment in apoE–/– mice fed high-fat diet (unpublished data).
Several lines of evidence point to the important role of
autoimmune processes in the development of atherosclero-
sis. The role of HSP60 as an initiator of atherogenesis is
currently intensively investigated. Its “molecular mimicry”
with HSP of Chlamydia has been recognized [44]. More-
over, the fact that anti-oxLDL antibodies resemble anti -
phospholipid antibodies, strengthen the concept of athero-
sclerosis as an autoimmune disease [26, 45, 46]. The
investigators also emphasize similarities in pathogenesis of
atherosclerosis and rheumatoid arthritis [47].
The inflammatory concept of atherosclerosis, formu-
lated just in the recent years, is an unquestionable achieve-
ment of science which also have specific therapeutic impli-
cations [48-54].
Animal models of atherosclerosis
The first evidence of experimental atherosclerosis came
into view as early as in 1908 when Ignatowski [55] report-
ed thickening of the intima with formation of large clear
cells in the aorta of rabbits fed a diet rich in animal proteins
(meat, milk, eggs).
The most useful animal models have for a long time
been restricted to relatively large animals, such as nonhu-
man primates, swine, and rabbits. Hamsters and pigeons
have been occasionally used, but present problems peculiar
to their species. Rats and dogs do not develop spontaneous
lesions and require heavy modifications of diet to produce
vascular lesion. Although rabbits do not develop sponta-
neous atherosclerosis they are highly responsive to choles-
terol manipulation and develop lesions in a fairly short time.
However, the lesions are much more fatty and macrophage-
rich (inflammatory) than the human lesions and plasma cho-
lesterol levels are extraordinarily high (very dissimilar to
humans). Pigs and monkeys are better suited to model
human atherosclerotic lesions. However, nowadays mon-
keys are not widely used due to obvious species-specific
concerns (risk of extinction) and costs. The pigs are a very
good model – when fed with cholesterol, they reach plas-
ma levels and atherosclerotic lesions that are quite similar
to those seen in humans. However, costs, the difficulties
involved in maintaining the colonies and in their handling
make this model inconvenient [56].
What has been lacking for long time was a small, genet-
ically reproducible, murine model of atherosclerosis. Such
a model could help to overcome the many problems and
deficiencies of larger animals and, in particular, would per-
mit studies of possible therapies that require relatively large
numbers of animals.
Until 1992, the majority of atherosclerotic research
focused on mechanisms in rabbits, with a lesser number of
studies in pigs and nonhuman primates. These large animal
models have provided invaluable insight. Studies in mon-
keys and rabbits have been pivotal in defining the cellular
events in the initiation and development of lesions [57]. In
recent years, there has been an explosion in the number of
in vivo studies what is largely attributable to the use of
mouse models to study atherogenic mechanisms.
Of mice and men – mouse as a model 
of atherosclerosis
Overall, mice are highly resistant to atherosclerosis. The
only exception is the C57BL/6 strain. These mice develop
atherosclerosis when fed a very high cholesterol diet con-
taining cholic acid, however, the vascular lesions in the
C57BL/6 differ from the human condition in the histolog-
ic nature and location and are possibly attributed to an
aggressive, chronic inflammatory state caused by cholic
acid administration.
The earliest mouse model of atherosclerosis was the
diet-induced model characterized during the 1960s in
Wissler’s laboratory. Special diet containing 30% fat, 5%
cholesterol, and 2% cholic acid led to atherosclerosis in
C57BL/6 mice. However, this was a very toxic causing lost
weight and often morbid respiratory infections. Paigen 
et al. modified this diet by blending it one part to three parts
with a 10% fat diet to yield what is called the “Paigen diet”
which consists of 15% fat, 1.25% cholesterol, and 0.5%
cholic acid [58].
Paigen and colleagues also developed assays that are
widely used to quantify atherosclerosis in the mouse mod-
els. The measurement of the cross-sectional lesion area in
the aortic root is the most standard assay [58]. Freshly per-
fused and isolated hearts are fixed in formalin, embedded
in gelatin, frozen, and cut into thin sections at anatomical-
ly defined sites in the aortic sinus and valve region. These
sections are stained for lipids, and the lesion area is meas-
ured microscopically.
Although this model has been widely employed, the
pathology of the lesions is not ideally suited as a model for
human atherosclerosis. This shortcoming led many inves-
tigators to downplay the role of the mouse as a good mod-
el of atherosclerosis. Lesion formation in the diet-induced
model is largely limited to the aortic root after feeding the
Paigen diet for periods of 14 weeks to 9 months. The lesions
are quite small, only several hundred to a few thousand
square micrometers, and they consist almost entirely of
macrophage foam cells with little evidence for smooth mus-
cle cell involvement. Thus, this model is largely limited to
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the fatty streak stage and does not progress to resemble
human intermediate lesions.
For many years the mouse was not used as an experi-
mental model for atherosclerosis research because of the
beliefs that mice could not survive on high-fat atherogenic
diets, that lesions are not reproducible (most mice do not
develop lesions), and that lesion pathology do not resem-
ble atherosclerosis in humans.
To judge the usefulness of animal model for athero-
sclerosis research the following questions should be asked:
1) what is the nature of the experimental lesions and their
similarity to human lesions; 2) is the plasma lipoprotein 
profile and metabolism similar to metabolism in humans;
3) what is the time frame necessary for lesions to form, and
how long does it take to breed the animals for the studies;
4) what is the cost of acquiring and maintaining the ani-
mals; 5) what is the ability to perform in vivo manipula-
tions and imaging; and 6) what is the ability of the model
to take advantage of classical and molecular genetic
approaches?
The average lifespan of a mouse is about 2 years, com-
pared to about 75 years in humans. Mice weigh much less,
about 30 grams for the adult. The lipid profile in the mouse
is very different from that in humans, who carry about 75%
of their plasma cholesterol on LDL. Mice carry most of their
cholesterol on high-density lipoprotein (HDL), which in
humans is considered protective. Mice fed their normal low-
fat chow diet do not develop atherosclerosis, while it is
a common in humans (one difference, which is an advan-
tage of all animal models, is the ability to control the envi-
ronment and diet in mouse studies, which is impossible for
long-term human studies). Also, the mouse immune sys-
tem, although well understood and readily manipulated,
diverges in many ways from that of humans (see below).
Human genetic studies are limited in range to various types
of association studies. With mice, on the other hand, many
additional kinds of genetic experiments are possible, includ-
ing breeding and genetic engineering [56].
Apolipoprotein E knockout mice –
a breakthrough in atherosclerotic research
It has been a long-standing goal of many investigators
around the world to create better mouse models for lipopro-
tein disorders and atherosclerosis and to identify genes that
may modify atherogenesis and lesion progression.
In 1992 apoE-deficient mice were generated by inacti-
vating the apoE gene by targeting [59]. The apoE gene was
inactivated in mouse embryonic stem (ES) cells by homol-
ogous recombination. Two targeting plasmids were used,
pJPB63 and pNMC109, both containing a neomycin-resis-
tance gene that replaced a part of the apoE gene and dis-
rupted its structure. Embryonic stem cell colonies targeted
after electroporation with plasmids were identified by the
polymerase chain reaction (PCR) followed by genomic
Southern analysis. Chimeric mice were generated by inject-
ing targeted cells into blastocysts. They gave strong
chimeras, which transmitted the disrupted apoE gene to their
progeny. Mice homozygous for the disrupted gene were
obtained from the heterozygotes. As the homozygous ani-
mals have been born at the expected frequency and they
appeared to be healthy, Piedrahita et al. demonstrated that
the lack of apoE did not interfere with normal development
of mice. At the same time another group also created apoE-
deficient mice [60]. Mice homozygous or heterozygous for
the disrupted apoE gene appeared healthy. No difference in
their body weight compared to normal mice was observed.
However, significant phenotypic differences between
normal animals and the homozygous mutants were observed
in their lipid and lipoprotein profiles. The apoE-knockout
mice had markedly (5 times) increased total plasma cho-
lesterol levels, regardless of the age or sex of the animals.
Although the total plasma cholesterol levels were greatly
elevated in the mutants, the high density lipoprotein (HDL)
cholesterol levels were only 45% of the normal level. The
triglyceride levels were 68% higher than those in normal
animals. (These apoE-deficient mice have had a dramatic
shift in plasma lipoproteins from HDL, the major lipopro-
tein in control mice, to cholesterol-enriched remnants of
chylomicrons and VLDL).
A chronological analysis of atherosclerosis development
in the apoE-deficient mice has shown that the sequential
events involved in lesion formation in this model are strik-
ingly similar to those in well-established larger animal mod-
els of atherosclerosis and in humans [61]. Animals as young
as 5-6 weeks of age have monocytic adhesions to the
endothelial surface of the aorta that can be appreciated read-
ily with electron microscopy (EM). Electron microscopy
also has demonstrated transendothelial migration of blood
monocytes in similarly aged mice. By 6-10 weeks of age,
most apoE-deficient mice have developed fatty-streak
lesions primarily consisting of foam cells with migrating
smooth muscle cells. These fatty-streak lesions rapidly
progress to advanced lesions, which are heterogeneous but
are typically composed of a necrotic core surrounded by
proliferating smooth muscle cells and varying amounts of
extracellular matrix, including collagen and elastin.
These lesions have well-formed fibrous caps made up
of smooth muscle cells and extracellular matrix that often
have groups of foam cells at their “shoulders”. It is not
uncommon for the inflammatory lesion to erode deep into
the medial wall of the aorta, and some of these animals
develop aortic aneurysms. Many of the lesions found in old-
er mice develop calcified foci [62].
The diet developed by Hayek et al. has been considered
a more physiological than Paigen diet; this “western-type”
diet for mouse studies is similar in composition to an aver-
age American diet of several years ago, consisting of 21%
fat by weight, 0.15% cholesterol, and no cholic acid. When
fed this diet, wild-type mice have a two-fold elevation in
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plasma cholesterol, while apoE-deficient mice have over
a three-fold elevation, to about 2000 mg/dl, again, mostly
in βVLDL, but there is also an increase in LDL [60]
(Table 1). The post-prandial clearance of intestinally derived
lipoproteins is dramatically impaired in apoE-deficient mice.
The apoE-deficient mice respond appropriately to a human-
like western-type diet [61]. On this diet, lesion formation
is greatly accelerated and lesion size is increased. In 
10-week old animals fed this diet for only 5 weeks, lesions
are 3-4 times the size of those observed in mice fed a low-
fat diet. In addition, monocytic adhesions and advanced
lesions develop at a significantly earlier age. The results of
this dietary challenge demonstrate that the mouse model
responds in an appropriate manner, i.e. increased fat leads
to increased plasma cholesterol, which in turn leads to
increased atherosclerosis. Moreover, the data suggest that
in addition to its histological similarity to humans, the
mouse model exhibits a response to environmental cues
resembling that of humans.
Lesions in the apoE-deficient mouse, as it is in humans,
tend to develop at vascular branch points and progress from
foam cell stage to the fibroproliferative stage with well-
defined fibrous caps and necrotic lipid cores, although
plaque rupture has not been observed in apoE-deficient mice
or in any other mouse model. Progression of lesions appears
to occur at a faster rate than in humans atherosclerosis; the
rapidity of lesion progression can be advantageous in many
experimental situations.
Comparing humans and apoE-deficient mice, lesion pro-
gression and cell types involved are similar, as is the pres-
ence of oxidized lipoproteins. However, the plaque rupture,
which is typical for all animal models of this disease and
fairly common in humans, is not observed in apoE-knock-
out mice. One potential reason for the lack of plaque rup-
ture in mice is that the diameter of the aorta is less than 
1 mm, which is even smaller than the diameter of the major
coronary arteries in humans. As the vessel diameter decreas-
es, the surface tension increases exponentially; thus, in the
mouse there may be so much surface tension that plaque
rupture would not be likely to occur.
ApoE-knockout mice are considered to be one of the
most relevant models for atherosclerosis since they are
hypercholesterolemic and develop spontaneous arterial
lesions. The apoE-deficient mouse contained the entire spec-
trum of lesions observed during atherogenesis and was the
first mouse model to develop lesions similar to those of
humans. This model provided opportunity to study the
pathogenesis and therapy of atherosclerosis in a small,
genetically defined animal.
As has been already mentioned, the method of meas-
urement of atherosclerosis by using the “aortic root” ather-
osclerosis assay was originally developed by Paigen et al.
Table 1. Comparison of lipid levels between wild mice and apoE-knockout mice
Animals Total cholesterol in mg/dl ±SD HDL cholesterol in mg/dl ±SD Triglyceride in mg/dl ±SD
normal 86 ±20 73 ±28 73 ±36
apoE-knockout mice 434 ±129 33 ±15 123 ±51
Fig. 1. Representative micrographs showing oil-red O stained “aortic roots” (“cross-sections”) from wild mice (A) and apoE-
knockout mice (B)
A B
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[58]. The aortic root “cross sectioning” assay (Fig. 1), wide-
ly used in murine studies of atherosclerosis, allows for coin-
cident inspection of lesion histology, and is amenable in
studies using large numbers of mice. Alternative measure-
ment of atherosclerosis, such as the “en face” (Fig. 2)
method also correlates with aortic root measurements. How-
ever, this method is less amenable for studies using large
numbers of mice and does not allow for inspection of lesion
histology.
Low-density lipoproteins receptor-deficient
mice
Gene targeting in embryonic stem cells has been used
to create LDL receptor-knockout (LDLR-KO) mice, a mod-
el of familial hypercholesterolemia. Low-density lipopro-
teins receptor-deficient mice were made in 1993 [63]. These
mice have a more modest lipoprotein abnormality than 
the apoE-deficient mice, with increases in LDL and VLDL
cholesterol leading to a total plasma cholesterol of about
250 mg/dl on a chow diet. Under such conditions LDL
receptor-deficient mice do not get atherosclerosis. However,
this is a very diet-responsive model. After these mice were
fed the Paigen diet, their plasma cholesterol levels soar to
about 1500 mg/dl, and large atherosclerotic lesions form [64].
It has also been shown that feeding the less toxic western-
type diet also leads to the development of large lesions, with
plasma cholesterol levels of about 400 mg/dl. The lesion
pathology in this model is not as well characterized as in
the apoE-deficient model, but it does appear similar in that
the lesions can progress beyond the foam-cell fatty-streak
stage to the fibro-proliferative intermediate stage.
Newest mice models
More recently, apoE and LDL-receptor (LDLr) double-
knockout (apoE/LDLr-DKO) mice have been created [64],
representing a new mouse model that develops severe
hyperlipidaemia and atherosclerosis [65]. It has been report-
ed that, even on a regular chow diet, the progression of ath-
erosclerosis is usually more marked in apoE/LDLr-DKO
mice than in mice deficient for apoE alone [66]. Thus, the
apoE/LDLr-DKO mouse is a suitable model to study the
anti-atherosclerotic effect of agents, without having to feed
the animals an atherogenic diet.
To study the contribution of endothelial nitric oxide syn-
thase (eNOS) to lesion formation apoE/eNOS double-
knockout mice were created [67]. It turned out that chron-
ic deficiency of eNOS increases atherosclerosis in apoE KO
mouse model. Furthermore, in the absence of eNOS, periph-
eral coronary disease, chronic myocardial ischemia, heart
failure, and an array of vascular complications develop that
have not been observed in apoE-KO animals.
Recently, Veniant et al. [68] managed to even up the
cholesterol levels in chow-fed apoE-KO mice and LDLR-
KO mice. They did so by making both mouse models
homozygous for the apolipoprotein B-100 allele, which
ameliorates the hypercholesterolemia in the setting of apoE
deficiency but worsens it in the setting of LDLR deficien-
cy. Moreover, the LDLR-KO Apob100/100 mice developed
extensive atherosclerosis even on a chow diet. So far this
model seems to be the best as concerns the development of
atherosclerosis in mice.
Immune mechanisms of atherosclerosis
The possibility that immune system might be involved
in atherogenesis emerged with the discovery of T cells and
macrophages in human atheromata [1]. Identification of
activation markers of almost all cell types involved in innate
and adaptive immunity in atheromatous plaques suggest
that immune cells in lesions are functionally significant [69].
Although the specific antigen has not been clearly iden-
tified, both cellular and humoral immune responses are gen-
erated in humans and experimental animals, possibly towards
LDL and HSP60. Based on the studies in mice, powerful pro-
atherogenic activity has been attributed to Th-1 cells pro-
ducing pro-inflammatory cytokines: IFN-γ and TNF-α [70].
On the other hand, atheroprotective signals are delivered by
regulatory T cells (Tregs) mainly by anti-inflammatory
cytokines, IL-10 and TGF-β, which countervail the pro-
inflammatory cytokines [71]. Hence, both stimulatory and
inhibitory mechanisms operate during atherogenesis. Progress
and challenges in translating the biology of atherosclerosis
has been described by Libby et al. [72].
In general, studies over past 20 years have proved that
apoE-deficient mouse model of atherosclerosis can be suc-
cessfully applied to: 1) identify atherosclerosis susceptibil-
Fig. 2. Representative Sudan-IV stained “en face” preparations
of aortas from wild mice (A) and apoE-knockout mice (B)
A B
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ity modifying genes, by the candidate-gene and gene-map-
ping methods; 2) identify the role of various cell types and
mediators (including immune cells and various cytokines)
in atherogenesis; 3) identify environmental factors affect-
ing atherogenesis; and 4) assess multiple therapies that
might partially block atherogenesis or lesion progression
[33, 52, 56, 73-77].
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